Insights
Search Results
Client Highlights
12.17.25
Wilson Sonsini Advises Aeovian Pharmaceuticals on Patent Matters Related to $55 Million Series B Financing
On December 16, 2025, Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing highly selective small molecule therapeutics that restore cellular metabolic quality control, announced it has closed an oversubscribed $55 million Series B financing that will fund completion of a Phase 2 proof-of-concept study for its lead development candidate, AV078, in tuberous sclerosis complex (TSC)-related refractory epilepsy. Proceeds from the financing will support the advancement of AV078 into a Phase 2 proof-of-concept study in participants with TSC-refractory epilepsy. Wilson Sonsini Goodrich & Rosati advised Aeovian Pharmaceuticals on patent matters related to the transaction.
Client Highlights
12.03.25
Wilson Sonsini Advises Solve Therapeutics on Patent Matters Related to $120 Million Financing
On November 17, 2025, Solve Therapeutics, a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates (ADCs) for solid tumor malignancies, announced it raised $120 million in an oversubscribed and upsized financing to accelerate the development of its clinical pipeline and proprietary CloakLink™ linker platform. This latest funding follows a $75 million financing completed in December 2024, bringing Solve’s total capital raised to $321 million. Wilson Sonsini Goodrich & Rosati advised Solve Therapeutics on patent matters related to the transaction.
Client Highlights
1.09.25
Wilson Sonsini Advises General Atlantic on IP Matters Related to Verdiva Bio’s Formation and $410 Million Series A
On January 9, 2025, Verdiva Bio Limited announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. Verdiva launched with an oversubscribed Series A financing of $411 million, co-led by General Atlantic and Forbion, with additional participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital (collectively, “the Investor Group”). Wilson Sonsini Goodrich & Rosati advised General Atlantic on IP matters related to Verdiva’s formation and Series A funding round.
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.
Client Highlights
10.23.24
Wilson Sonsini Advises General Atlantic on Patent Matters Related to Seaport Therapeutics' Oversubscribed $225 Million Series B
On October 21, 2024, Seaport Therapeutics, a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines, announced the completion of an oversubscribed $225 million Series B financing round. The funding was led by General Atlantic, a leading global growth investor, with participation from funds and accounts advised by T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, CPP Investments, and other new investors. Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and co-founder PureTech Health also participated. Wilson Sonsini Goodrich & Rosati advised General Atlantic on patent matters related to the transaction.
Client Highlights
9.17.24
Wilson Sonsini Advises MBX Biosciences on Patents Matters Related to IPO
On September 16, 2024, MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, announced the closing of its upsized initial public offering. The aggregate gross proceeds from the offering were approximately $187.7 million, before deducting underwriting discounts and commissions and offering expenses. Wilson Sonsini Goodrich & Rosati advised MBX Biosciences on patent matters related to the upsized IPO.
Client Highlights
8.06.24
Firm Advises MBX Biosciences on Patent Matters Related to $63.5 Million Series C Financing
On August 5, 2024, MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, announced a $63.5 million Series C financing. The financing was led by Deep Track Capital, with participation from new investors Driehaus Capital Management and funds and accounts advised by T. Rowe Price Associates, Inc., as well as existing investors Frazier Life Sciences, OrbiMed, and Wellington Management, complementing the company’s existing investor base, including New Enterprise Associates (NEA), Norwest Venture Partners, and RA Capital Management. Wilson Sonsini Goodrich & Rosati represents MBX Biosciences on patent matters, and advised the company on patent matters related to this Series C financing.
The proceeds from the transaction are expected to support MBX Biosciences into 2026 and past key data read-outs from the company’s pipeline. The Phase 2 clinical trial of MBX 2109, the company’s parathyroid hormone peptide prodrug, in patients with hypoparathyroidism was recently initiated and topline results are expected in the third quarter of 2025. MBX 1416, the company’s product candidate for post-bariatric hypoglycemia, is currently being evaluated in a Phase 1 single and multiple ascending dose trial, which is expected to report topline data in the fourth quarter of 2024. MBX also has a portfolio of early-stage candidates in obesity and metabolic disease, including MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug currently in IND-enabling studies.
The Wilson Sonsini team was led by Uale Taotafa and included Nima Zargari, Jose Martinez, T.J. O’Connor, and Mike Hostetler.
For more information, please see MBX Biosciences’ news release.
The proceeds from the transaction are expected to support MBX Biosciences into 2026 and past key data read-outs from the company’s pipeline. The Phase 2 clinical trial of MBX 2109, the company’s parathyroid hormone peptide prodrug, in patients with hypoparathyroidism was recently initiated and topline results are expected in the third quarter of 2025. MBX 1416, the company’s product candidate for post-bariatric hypoglycemia, is currently being evaluated in a Phase 1 single and multiple ascending dose trial, which is expected to report topline data in the fourth quarter of 2024. MBX also has a portfolio of early-stage candidates in obesity and metabolic disease, including MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug currently in IND-enabling studies.
The Wilson Sonsini team was led by Uale Taotafa and included Nima Zargari, Jose Martinez, T.J. O’Connor, and Mike Hostetler.
For more information, please see MBX Biosciences’ news release.
Client Highlights
4.04.24
Wilson Sonsini Advises Aeovian Pharmaceuticals on Patent Matters Related to $50 Million Series A
On March 28, 2024, Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, announced it has completed a $50 million Series A financing extension, led by Hevolution. Existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture also participated in the Series A round. Wilson Sonsini Goodrich & Rosati advised Aeovian Pharmaceuticals on patent matters related to the transaction, and manages Aeovian’s patent portfolio strategy.
In addition to the Series A financing, Aeovian also announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer.
In addition to the Series A financing, Aeovian also announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer.
Client Highlights
4.04.24
Wilson Sonsini Advises ProfoundBio on Patent Matters related to Acquisition by Genmab
On April 3, 2024, Genmab A/S and ProfoundBio, Inc. announced that the companies have entered into a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction. ProfoundBio is a privately-owned clinical-stage biotechnology company developing next-generation ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRα-expressing solid tumors. Wilson Sonsini Goodrich and Rosati advised ProfoundBio on patent matters related to the transaction.
Genmab will acquire ProfoundBio for $1.8 billion in cash, payable at closing. The proposed transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the first half of 2024, and is subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised ProfoundBio on patent matters related to the transaction includes Julia Minitti, Feng Tian, Hee Min Noh, and Jose Martinez.
For more information, please see ProfoundBio’s press release.
Genmab will acquire ProfoundBio for $1.8 billion in cash, payable at closing. The proposed transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the first half of 2024, and is subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised ProfoundBio on patent matters related to the transaction includes Julia Minitti, Feng Tian, Hee Min Noh, and Jose Martinez.
For more information, please see ProfoundBio’s press release.
Client Highlights
12.15.23
Wilson Sonsini Advises Valor Capital, Hack VC on Series Seed Investment in Nonco
On December 11, 2023, Nonco, an institutional digital asset brokerage firm, announced it has raised $10 million of aggregate new capital in a Seed investment round led by Valor Capital Group and Hack VC. The round was a combination of equity and convertible notes and, in addition to the investment from Valor Capital and Hack VC, included investments from Morgan Creek Digital, Bullish, CMCC, Lvna Capital, Theta Capital, Bastion Trading, Libra Capital Ventures, and others. Nonco will use the capital to continue its growth and serve the Americas' growing institutional demand.
Client Highlights
10.27.21
Firm Advises Quanta Therapeutics on IP Matters Related to $60 Million Series C
On October 26, 2021, Quanta Therapeutics, Inc., a privately held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancer types, announced that it has successfully closed a $60 million Series C financing round led by Surveyor Capital (a Citadel company) and Vida Ventures. New investors Longitude Capital and BVF Partners joined existing investors Sofinnova Investments, Logos Capital, AbbVie Ventures, and Vida Ventures in the financing. Wilson Sonsini Goodrich & Rosati provided IP counsel to Quanta in connection with the Series C transaction.
Quanta will use the proceeds from the financing to advance programs targeting RAF1 and KRAS through clinical candidate selection and IND filing to reach initial proof-of-concept. Leveraging a differentiated mechanism targeting the active conformation of RAS, the Quanta team believes their unique approach, with applicability across mutant RAS forms, will circumvent resistance mechanisms experienced with first-generation inhibitors of KRAS G12C.
The Wilson Sonsini patents and innovations team that advised Quanta with respect to the financing was led by Julia Minitti and included Josh Seitz, Luis Perla, Jose Martinez, and Mike Hostetler.
For more information, please see Quanta’s press release.
Quanta will use the proceeds from the financing to advance programs targeting RAF1 and KRAS through clinical candidate selection and IND filing to reach initial proof-of-concept. Leveraging a differentiated mechanism targeting the active conformation of RAS, the Quanta team believes their unique approach, with applicability across mutant RAS forms, will circumvent resistance mechanisms experienced with first-generation inhibitors of KRAS G12C.
The Wilson Sonsini patents and innovations team that advised Quanta with respect to the financing was led by Julia Minitti and included Josh Seitz, Luis Perla, Jose Martinez, and Mike Hostetler.
For more information, please see Quanta’s press release.
Client Highlights
2.19.21
Wilson Sonsini Advises General Atlantic on Patent Matters Related to Centessa Pharmaceuticals' Launch and $250 Million Series A
On February 16, 2021, Centessa Pharmaceuticals (Centessa) launched as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs. Centessa’s asset-centric R&D model applied at scale has assembled best-in-class or first-in-class assets, each of which is led by specialized teams committed to accelerate development and reshape the traditional drug development process.